RxDoctor Payments Data

Shajitha Nawaz, MD

Psychiatry · Temecula, CANPI 1659476331

Payments from drug & device makers

$591in general payments, 2019–2025

Across 30 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$244
  • Axsome Therapeutics, Inc.$87
  • Otsuka America Pharmaceutical, Inc.$78
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • Neurocrine Biosciences, Inc.$31
  • AbbVie$30
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$51487%
  • Education$7713%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$591 in reported general payments places this provider in the 65th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$11,981
Medicare patients
59
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole251$361,570
Invega TrinzaPaliperidone Palmitate43$223,719
Invega SustennaPaliperidone Palmitate93$206,009
VraylarCariprazine Hcl92$136,671
IngrezzaValbenazine Tosylate12$106,410
TrintellixVortioxetine Hydrobromide88$62,936
Abilify MaintenaAripiprazole23$45,068
CaplytaLumateperone Tosylate25$40,897
LybalviOlanzapine/Samidorphan Malate17$25,794
VivitrolNaltrexone Microspheres15$21,946
Lurasidone Hcl69$11,823
Paliperidone ErPaliperidone43$6,440
SaphrisAsenapine Maleate11$6,324
Divalproex Sodium ErDivalproex Sodium184$5,176
ViibrydVilazodone Hcl13$4,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$13$429,728136 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$78$406,638274 claims
AbbVieVraylar, Saphris, Viibryd$30$147,222116 claims
Neurocrine Biosciences, Inc.Ingrezza$31$106,41012 claims
Alkermes, Inc.Lybalvi, Vivitrol$19$47,74032 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$47$40,89725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →